Li Kang Biomedical Co., Ltd. Share Price

Equities

6242

TW0006242001

Food Processing

End-of-day quote Taipei Exchange 23:00:00 14/05/2024 BST 5-day change 1st Jan Change
50.5 TWD 0.00% Intraday chart for Li Kang Biomedical Co., Ltd. -2.51% -13.38%

Financials

Sales 2022 684M 21.34M 1.68B Sales 2023 629M 19.63M 1.55B Capitalization 1.56B 48.74M 3.84B
Net income 2022 112M 3.49M 275M Net income 2023 111M 3.46M 273M EV / Sales 2022 1.54 x
Net cash position 2022 263M 8.22M 647M Net cash position 2023 210M 6.56M 516M EV / Sales 2023 2.15 x
P/E ratio 2022
11.8 x
P/E ratio 2023
14.2 x
Employees -
Yield 2022
3.55%
Yield 2023
-
Free-Float 33.81%
More Fundamentals * Assessed data
Dynamic Chart
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Li Kang Biomedical Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
More news
1 week-2.51%
Current month-3.44%
1 month-4.54%
3 months-7.68%
6 months-10.46%
Current year-13.38%
More quotes
1 week
50.20
Extreme 50.2
51.60
1 month
50.20
Extreme 50.2
53.00
Current year
50.20
Extreme 50.2
58.80
1 year
50.20
Extreme 50.2
70.52
3 years
31.06
Extreme 31.0559
71.30
5 years
24.27
Extreme 24.265
71.30
10 years
15.67
Extreme 15.6678
71.30
More quotes
Managers TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 19/10/14
Members of the board TitleAgeSince
Chief Executive Officer - -
Director/Board Member - 24/08/14
Director/Board Member - 24/08/14
More insiders
Date Price Change Volume
15/05/24 50.5 0.00% 54,199
14/05/24 50.5 -0.59% 17,863
13/05/24 50.8 -1.17% 36,502
10/05/24 51.4 0.00% 14,752
09/05/24 51.4 -0.77% 17,737

End-of-day quote Taipei Exchange, May 14, 2024

More quotes
Li Kang Biomedical Co., Ltd. formerly BAFO TECHNOLOGIES CORP., is engaged in the manufacture and sale of computer, communication and consumer (3C) product cables and circumscribed computer peripheral products, as well as communication products. The Company offers unshielded twisted pair (UTP) cables, monitor cables, small computer system interface (SCSI) cables, universal serial bus (USB) cables, wireless hopping/mesh access points, wireless modules, and wireless vehicle communication systems, among others. The Company distributes its products within the domestic market and to overseas markets, including Europe, the Americas and the rest of Asia.
More about the company